论文部分内容阅读
目的探讨普米克气雾剂联合孟鲁司特治疗哮喘患儿的临床疗效。方法选取2014年1月至2015年1月山东省济宁市金乡县计划生育妇幼保健服务中心收治的72例哮喘患儿作为研究对象,按随机数字表法将其分为对照组和试验组,各36例。对照组患儿采用普米克气雾剂进行治疗,试验组患儿在对照组基础上睡前服用孟鲁司特钠颗粒,比较两组患儿的临床治疗效果、症状改善情况、肺功能及不良反应发生情况。结果试验组患儿治疗的总有效率明显高于对照组,差异有统计学意义(P<0.05);治疗后,试验组患儿的日间症状、夜间症状评分均明显低于对照组,差异均有统计学意义(均P<0.05);试验组患儿的PEF、FEV1均明显高于对照组,差异均有统计学意义(均P<0.05)。而两组患儿不良反应,差异无统计学意义(P>0.05)。结论普米克气雾剂联合孟鲁司特治疗小儿哮喘临床效果更佳,能减轻患儿的临床症状,改善肺功能,且不良反应较少,是一种安全有效的治疗方案。
Objective To investigate the clinical efficacy of pulmicort aerosol combined with montelukast in children with asthma. Methods Seventy-two asthmatic children, who were treated at the Maternal and Child Health Care Service Center of Jinxiang County, Jining City, Shandong Province from January 2014 to January 2015, were selected as research subjects and divided into control group and experimental group according to random number table method. 36 cases in each. Children in the control group were treated with Pulmicort Aerosol. The children in the test group were given montelukast sodium granules before going to bed at bedtime. The clinical effects, symptom improvement, lung function and mal-function of the two groups were compared Reaction occurred. Results The total effective rate in treatment group was significantly higher than that in control group (P <0.05). After treatment, the scores of daytime symptoms and nocturnal symptoms of children in test group were significantly lower than those in control group (P <0.05). The PEF and FEV1 in the experimental group were significantly higher than those in the control group (all P <0.05). The two groups of children with adverse reactions, the difference was not statistically significant (P> 0.05). Conclusion Pulmicort aerosol combined with montelukast is a safe and effective treatment for children with asthma, which can reduce the clinical symptoms and improve lung function in children with less adverse reactions.